View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	May 11, 2020
Document Information [Line Items]
Entity Registrant Name	Vaxart, Inc.
Entity Central Index Key	0000072444
Trading Symbol	vxrt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		74,184,322
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.10 par value

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 29,859	$ 13,526
Accounts receivable	2,663	3,619
Prepaid expenses and other current assets	1,143	453
Total current assets	33,665	17,598
Property and equipment, net	191	210
Right-of-use assets, net	1,910	1,990
Intangible assets, net	16,660	17,093
Other long-term assets	138	141
Total assets	52,564	37,032
Current liabilities:
Accounts payable	793	852
Current portion of operating lease liability	855	841
Liability related to sale of future royalties, current portion	1,513	2,916
Other accrued liabilities	4,280	4,565
Total current liabilities	7,441	9,174
Operating lease liability, net of current portion	1,271	1,472
Liability related to sale of future royalties, net of current portion	12,541	13,416
Other long-term liabilities	18	18
Total liabilities	21,271	24,080
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock: $0.10 par value; 5,000,000 shares authorized; none issued and outstanding as of March 31, 2020 and December 31, 2019
Common stock: $0.10 par value; 100,000,000 shares authorized; 72,004,720 and 48,254,994 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	7,200	4,825
Additional paid-in capital	142,051	124,788
Accumulated deficit	(117,958)	(116,661)
Total stockholders’ equity	31,293	12,952
Total liabilities and stockholders’ equity	$ 52,564	$ 37,032

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	72,004,720	48,254,994
Common stock, shares outstanding (in shares)	72,004,720	48,254,994

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Revenue	$ 2,902	$ 5,407
Operating expenses:
Research and development	1,542	3,829
General and administrative	1,990	2,026
Restructuring costs	64
Total operating expenses	3,596	5,855
Operating loss	(694)	(448)
Other income and (expenses):
Interest income	41	5
Interest expense		(107)
Non-cash interest expense related to sale of future royalties	(491)	(544)
Foreign exchange gain, net		5
Total other income and (expenses)	(450)	(641)
Net loss before income taxes	(1,144)	(1,089)
Provision for income taxes	153	250
Net loss	$ (1,297)	$ (1,339)
Net loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.18)
Shares used to compute net loss per share - basic and diluted (in shares)	60,677,145	7,301,189
Customer Service Contracts [Member]
Revenue:
Revenue	$ 99
Royalty [Member]
Revenue:
Revenue	2,769	3,659
Non Cash Royalty Revenue [Member]
Revenue:
Revenue	$ 34	$ 1,748

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Placement Agents' Designees [Member] Additional Paid-in Capital [Member]	Placement Agents' Designees [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2018			7,141,189	108,513					7,141,189	108,513
Balances at Dec. 31, 2018	$ (27)	$ (27)	$ 714		$ (98,016)	$ 11,211			$ 714		$ (97,989)	$ 11,238
Issuance of common stock and warrants, net of offering costs (in shares)									1,200,000	2,320
Issuance of common stock and warrants, net of offering costs									$ 120			2,440
Issuance of common stock warrants to placement agents’ designees								$ 100
Stock-based compensation												164
Net loss											(1,339)	(1,339)
Balances (in shares) at Mar. 31, 2019									8,341,189	111,097
Balances at Mar. 31, 2019									$ 834		(99,355)	12,576
Balances (in shares) at Dec. 31, 2018			7,141,189	108,513					7,141,189	108,513
Balances at Dec. 31, 2018	$ (27)	$ (27)	$ 714		$ (98,016)	$ 11,211			$ 714		(97,989)	11,238
Balances (in shares) at Dec. 31, 2019									48,254,994
Balances at Dec. 31, 2019									$ 4,825	$ 124,788	(116,661)	12,952
Issuance of common stock and warrants, net of offering costs (in shares)									4,000,000
Issuance of common stock and warrants, net of offering costs									$ 400	8,322		8,722
Issuance of common stock warrants to placement agents’ designees							$ 453	$ 453
Stock-based compensation												96
Net loss											(1,297)	(1,297)
Balances (in shares) at Mar. 31, 2020									72,004,720
Balances at Mar. 31, 2020									$ 7,200	142,051	(117,958)	31,293
Issuance of common stock upon exercise of common stock warrants (in shares)									19,726,120
Issuance of common stock upon exercise of common stock warrants									$ 1,973	8,376		$ 10,349
Issuance of common stock upon exercise of stock options (in shares)									23,606			23,606
Issuance of common stock upon exercise of stock options									$ 2	$ 16		$ 18

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Offering costs from issuance of common stock and warrants	$ 1,278	$ 560

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,297)	$ (1,339)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	580	1,100
Stock-based compensation	96	164
Non-cash interest expense		35
Non-cash interest expense related to sale of future royalties	491	544
Non-cash revenue related to sale of future royalties	(2,769)	(1,384)
Change in operating assets and liabilities:
Accounts receivable	956	(3,788)
Prepaid expenses and other assets	(690)	100
Accounts payable	(55)	(184)
Other accrued liabilities	(520)	99
Net cash used in operating activities	(3,208)	(4,653)
Cash flows from investing activities:
Purchase of property and equipment	(4)	(552)
Proceeds from sale of equipment	3
Net cash used in investing activities	(1)	(552)
Cash flows from financing activities:
Net proceeds from issuance of securities in registered direct offering	9,175	2,540
Proceeds from issuance of common stock upon exercise of common stock warrants	10,349
Proceeds from issuance of common stock upon exercise of stock options	18
Repayment of principal on secured promissory note payable to Oxford Finance		(417)
Net cash provided by financing activities	19,542	2,123
Net increase (decrease) in cash and cash equivalents	16,333	(3,082)
Cash, cash equivalents and restricted cash at beginning of the period	13,526	11,506
Cash, cash equivalents and restricted cash at end of the period	29,859	8,424
Supplemental disclosure of cash flow information:
Interest paid		72
Supplemental disclosure of non-cash financing activity:
Issuance of warrants to placement agent’s representatives	453	100
Acquisition of property and equipment included in accounts payable		$ 123

Note 1 - Organization and Basis of Presentation	3 Months Ended
Note 1 - Organization and Basis of Presentation	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. Organization and Basis of Presentation General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, under the name West Coast Biologicals, Inc. The Company changed its name to Vaxart, Inc. (“Private Vaxart”) in July 2007, and reincorporated in the state of Delaware. On February 13, 2018, Private Vaxart completed a business combination with Aviragen Therapeutics, Inc. (“Aviragen”), pursuant to which Aviragen merged with Private Vaxart, with Private Vaxart surviving as a wholly-owned subsidiary of Aviragen (the “Merger”). Pursuant to the terms of the Merger, Aviragen changed its name to Vaxart, Inc. (together with its subsidiaries, the “Company” or “Vaxart”) and Private Vaxart changed its name to Vaxart Biosciences, Inc. All of Private Vaxart’s convertible promissory notes and convertible preferred stock was converted into common stock, following which each share of common stock was converted into approximately 0.22148 shares of the Company’s common stock (the “Conversion”). On March 2, 2020, the Company completed a registered direct offering (the “March 2020 Offering”) of 4,000,000 shares of the Company’s common stock and warrants to purchase 2,000,000 shares of common stock. Each common stock warrant entitles the holder to purchase one share of common stock for $2.50, is exercisable immediately, subject to certain ownership limitations, and will expire five years from the date of issuance. The total gross proceeds from the offering to the Company were $10.0 million. After deducting placement agent fees and offering expenses payable by the Company, the aggregate net proceeds received by the Company totaled $9.2 million. Pursuant to the terms of the engagement letter with the placement agents, the Company paid the placement agents aggregate fees and reimbursable costs of $775,000. In addition, the Company issued the placement agents’ designees 280,000 common stock warrants at the closing of the March 2020 Offering, each warrant entitling the holder to purchase one share of common stock for $3.125 at any time within five years of the effective date of the March 2020 Offering. The aggregate fair value of these warrants at issuance was estimated to be $453,000 (see Note 10 ), which was recorded in offering costs. The Company’s principal operations are based in South San Francisco, California, and it operates in one reportable segment, which is the discovery and development of oral recombinant protein vaccines, based on its proprietary oral vaccine platform.

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
Note 2 - Summary of Significant Accounting Policies	Mar. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Summary of Significant Accounting Policies Basis of Presentation – The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to these rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10 -K filed with the SEC on March 19, 2020 ( the “Annual Report”). Except as noted below, there have been no material changes to the Company’s significant accounting policies described in Note 2 to the consolidated financial statements included in the Annual Report. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year. Basis of Consolidation – The condensed consolidated financial statements include the financial statements of Vaxart, Inc. and its subsidiaries. All significant transactions and balances between Vaxart, Inc. and its subsidiaries have been eliminated in consolidation. Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions. Concentration of Credit Risk – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company places its cash and cash equivalents at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. The Company has not experienced any losses on its deposits since inception. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating. The Company generally requires no collateral from its customers. Reclassification – Prior periods’ data is subject to reclassification to conform to the current presentation. Accordingly, $48,000 that was previously recorded as non-lease costs has been included as variable lease costs and in cash outflows related to leases in the three months ended March 31, 2019. This reclassification had no effect on reported net loss. Recent Accounting Pronouncements The Company has reviewed all newly-issued accounting pronouncements and concluded that they either are not applicable to the Company’s operations or no material effect is expected on its condensed consolidated financial statements as a result of future adoption.

Note 3 - Fair Value of Financial Instruments	3 Months Ended
Note 3 - Fair Value of Financial Instruments	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3 . Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three -level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three -level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 – Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 – Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s money market funds are classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets for identical securities. The Company held no recurring financial assets that are measured at fair value as of March 31, 2020. The Company held $15,000 in money market funds, classified as cash equivalents, as of December 31, 2019. The Company held no recurring financial liabilities at either date or in the three months ended March 31, 2020 or 2019.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 4 - Balance Sheet Components

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

NOTE

Balance Sheet Components

(a)

Cash and Cash Equivalents

Cash and cash equivalents comprises the following:

	March 31, 2020		December 31, 2019
	(in thousands)
Cash at banks	$	29,859	$	13,511
Money market funds		—		15
Total cash and cash equivalents	$	29,859	$	13,526

(b)

Accounts Receivable

Accounts receivable comprises the following:

	March 31, 2020		December 31, 2019
	(in thousands)
Royalties receivable	$	2,663	$	3,438
Customer service contracts - billed		—		181
Accounts receivable	$	2,663	$	3,619

The Company has provided

allowance for uncollectible accounts as of

March 31, 2020

and

December 31, 2019.

(c)

Property and Equipment, Net

Property and equipment, net consists of the following:

	March 31, 2020			December 31, 2019
	(in thousands)
Laboratory equipment	$	537		$	537
Office and computer equipment		132			132
Total property and equipment		669			669
Less: accumulated depreciation		(478	)		(459	)
Property and equipment, net	$	191		$	210

Depreciation expense for the

three

months ended

March 31,

2020

and

2019

, was

$19,000

and

$130,000,

respectively. There were

impairments of the Company’s property and equipment recorded in the

three

months ended

March 31,

2020

2019

(d)

Right-of-Use Assets

, Net

Right-of-use assets, net consists of the following:

	March 31, 2020		December 31, 2019
	(in thousands)
Facilities	$	1,906	$	1,985
Office equipment		4		5
Right-of-use assets, net	$	1,910	$	1,990

(e)

Intangible Assets

Intangible assets comprise developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from

1.3

11.75

years for developed technology and

years for intellectual property. As of

March 31, 2020,

developed technology and intellectual property had remaining lives of

9.6

and

7.75

years, respectively. Intangible assets consist of the following:

	March 31, 2020			December 31, 2019
	(in thousands)
Purchased technology	$	22,100		$	22,100
Intellectual property		80			80
Total cost		22,180			22,180
Less: accumulated amortization		(5,520	)		(5,087	)
Intangible assets, net	$	16,660		$	17,093

Total amortization expense was

$433,000

and

$779,000

in the

three

months ended

March 31,

2020

and

2019

, respectively.

As of

March 31, 2020

, the estimated future amortization expense by year is as follows (in thousands):

Year Ending December 31,	Amount
2020 (nine months remaining)	$	1,299
2021		1,732
2022		1,731
2023		1,732
2024		1,732
Thereafter		8,434
Total	$	16,660

(f)

Other Accrued Liabilities

Other accrued liabilities consist of the following:

	March 31, 2020		December 31, 2019
	(in thousands)
Accrued compensation	$	461	$	903
Accrued clinical and manufacturing expenses		3,228		3,228
Accrued professional and consulting services		207		2
Reserve for return of royalties		178		178
Other liabilities, current portion		206		254

Total	$	4,280	$	4,565

Note 5 - Revenue	3 Months Ended
Note 5 - Revenue	Mar. 31, 2020
Notes to Financial Statements
Revenue [Text Block]	NOTE 5 . Revenue Service Contracts with Customers Contract Balances. Accounts receivable related to service contracts with customers as of March 31, 2020 and December 31, 2019, was nil and $181,000, respectively. Contract assets, representing unbilled receivables where revenue has been recognized in advance of customer billings, as of March 31, 2020 and December 31, 2019, was $120,000 and $21,000, respectively, which is included in prepaid expenses and other current assets. Remaining Performance Obligations. Remaining Performance Obligations (“RPO”) comprise deferred revenue plus unbilled contract revenue. As of March 31, 2020 and December 31, 2019, there was no deferred revenue and the aggregate amount of RPO was $112,000 and $211,000, respectively, all of which was unbilled contract revenue which is not recorded on the balance sheet. We expect 100% of this amount to be recognized as revenue within the next three months, subject to unforeseen delays. Unbilled contract revenue represents non-cancelable contracts under which the Company has an obligation to perform, for which revenue has not yet been recognized in the financial statements and the fixed amounts billable have not yet been invoiced. Royalty Agreements Aviragen entered into a royalty-generating research and license agreement with GlaxoSmithKline, plc (“GSK”) in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor marketed by GSK as Relenza, to treat influenza. Under the agreement, all Relenza patents owned by the Company were exclusively licensed to GSK. All of the Company’s Relenza patents have expired, with the last remaining patent expiring in July 2019 in Japan, at which time royalty revenue ceased, although it remains subject to minor adjustments for sales returns and exchange rate differences. The Company recognized no royalty revenue related to Relenza in the three months ended March 31, 2020 and recognized $695,000 in the three months ended March 31, 2019, representing 7% of net sales in Japan. The Company also generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in 2009. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children, which Daiichi Sankyo markets as Inavir. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir in Japan. The last patent related to Inavir is set to expire in December 2029, at which time royalty revenue will cease. The royalty revenue related to Inavir recognized in the three months ended March 31, 2020 and 2019, was $2,769,000 and $2,964,000, respectively, representing 4% of net sales in Japan. In addition, the Company recognized non-cash royalty revenue related to the sale of future royalties (see Note 6 ) of $34,000 and $1,748,000 in the three months ended March 31, 2020 and 2019, respectively. Both the royalty revenue and the non-cash royalty revenue related to the sale of future royalties have been subjected to a 5% withholding tax in Japan, for which $140,000 and $236,000 was included in income tax expense in the three months ended March 31, 2020 and 2019, respectively. The Company’s royalty revenue is seasonal, in line with the flu season, so the majority of the Company’s royalty revenue is earned in the first and fourth fiscal quarters.

Note 6 - Liabilities Related to Sale of Future Royalties

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

NOTE

Liabilities Related to Sale of Future Royalties

April 2016,

Aviragen entered into a Royalty Interest Acquisition Agreement (the “RIAA”) with HealthCare Royalty Partners III, L.P. (“HCRP”). Under the RIAA, HCRP made a

$20.0

million cash payment to Aviragen in consideration for acquiring certain royalty rights (“Royalty Rights”) related to the approved product Inavir in the Japanese market. The Royalty Rights were obtained pursuant to the collaboration and license agreements (the “License Agreement”) and a commercialization agreement that the Company entered into with Daiichi Sankyo. Per the terms of the RIAA, HCRP is entitled to the

first

$3.0

million plus

15%

of the next

$1.0

million in royalties earned in each year commencing on

April 1,

with any excess revenue being retained by the Company.

Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction is accounted for as a liability that is being amortized using the interest method over the life of the arrangement. The Company has

obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. In order to record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement and the payments that will be passed through to HCRP over the life of this agreement. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The royalties earned in each period that will be passed through to HCRP are recorded as non-cash royalty revenue related to sale of future royalties, with any excess

not

subject to pass-through being recorded as royalty revenue. When the pass-through royalties are paid to HCRP in the following quarter, the imputed liability related to sale of future royalties is commensurately reduced. The Company periodically assesses the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company adjusts the amortization of the liability and interest rate. As a result of this accounting, even though the Company does

not

retain HCRP’s share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability, including the related interest, is fully amortized.

The following table shows the activity within the liability account during the

three

months ended

March 31,

2020

(in thousands):

Total liability related to sale of future royalties, start of period	$	16,332
Non-cash royalty revenue paid to HCRP		(2,769	)
Non-cash interest expense recognized		491
Total liability related to sale of future royalties, end of period		14,054
Current portion		(1,513	)
Long-term portion	$	12,541

Note 7 - Leases

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

NOTE

Leas

The Company has obtained the right of use for office and manufacturing facilities under

four

operating lease agreements,

one

of which has been subleased, and for equipment under an operating lease agreement with an initial term exceeding

one

year, and under

three

operating lease agreements with initial terms of

one

year or less.

The Company obtained the right of use of real estate located in South San Francisco, California, in

June 2015

that was scheduled to terminate on

April 30, 2020,

with a

five

-year extension option that the Company exercised in

July 2019,

extending the lease until

April 30, 2025.

The right of use of these premises was assessed as partially impaired as of

December 31, 2019 (

see Note

). The Company also obtained, via the Merger in

February 2018,

the right of use of facilities located in Alpharetta, Georgia, that terminates on

February 28, 2021,

with

extension option. These facilities were subleased for the remainder of the lease term effective

November 30, 2018.

In addition, the Company has the right of use of

two

facilities located in South San Francisco, California, under leases that terminate on

July 31, 2021,

with

extension options, and the right of use of equipment under a lease that terminates in

September 2021.

As of

March 31, 2020,

the weighted average discount rate for operating leases with initial terms of more than

one

year was

10.53%

and the weighted average remaining term of these leases was

3.62

years. Discount rates were determined using the Company’s marginal rate of borrowing at the time each lease was executed or extended.

The following table summarizes the Company’s undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than

twelve

months as of

March 31, 2020 (

in thousands):

Year Ending December 31,
2020 (excluding the three months ended March 31, 2020)	$	781
2021		620
2022		336
2023		348
2024		360
Thereafter		121
Undiscounted total		2,566
Less: imputed interest		(440	)
Present value of future minimum payments		2,126
Current portion of operating lease liability		(855	)
Operating lease liability, net of current portion	$	1,271

The Company presently has

finance leases and

future obligations under operating leases for equipment with initial terms of

one

year or less.

Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Operating lease expenses for the

three

months ended

March 31, 2020

and

2019,

are summarized as follows:

	Three Months Ended March 31,
	2020			2019
Lease cost	(in thousands)
Operating lease cost	$	189		$	223
Short-term lease cost		3			3
Variable lease cost		11			48
Sublease income		(54	)		(54	)
Total lease cost	$	149		$	220

Net cash outflows associated with operating leases totaled

$237,000

and

$247,000

in the

three

months ended

March 31, 2020

and

2019,

respectively.

Note 8 - Secured Promissory Note Payable to Oxford Finance	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Secured Promissory Note Payable [Text Block]	NOTE 8 . Secured Promissory Note Payable to Oxford Finance On December 22, 2016, the Company entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance, under which the Company borrowed $5.0 million. The $5.0 million loan, which bore interest at the 30 -day U.S. LIBOR plus 6.17%, was evidenced by a secured promissory note and was repayable over four years, with interest only payable over the first 12 months and the balance fully amortized over the subsequent 36 months. Upon repayment, an additional final payment equal to $325,000 was due, which was accreted as interest expense over the term of the loan using the effective-interest method. The loan was secured by substantially all the Company’s assets, except for intellectual property. The annual effective interest rate of the note, including the accretion of the final payment and the amortization of the debt discount, was approximately 10.5%. The Company recorded interest expense related to the Loan Agreement of $106,000, of which $72,000 was paid, during the three months ended March 31, 2019. The note was repaid in full on November 4, 2019.

Note 9 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

NOTE

. Commitments and Contingencies

(a)

Leases

The Company’s lease commitments are detailed in Note

(b)

Indemnifications

In the ordinary course of business, the Company enters into agreements that

may

include indemnification provisions. Pursuant to such agreements, the Company

may

indemnify, hold harmless and defend indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from

third

-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is

not

determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that

may

require the Company to indemnify its directors and officers against liabilities that

may

arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance.

(c)

Litigation

From time to time the Company

may

be involved in claims arising in connection with its business. Based on information currently available, the Company believes that the amount, or range, of reasonably possible losses in connection with any pending actions against it in excess of established reserves, in the aggregate,

not

to be material to its consolidated financial condition or cash flows. However, losses

may

be material to the Company’s operating results for any particular future period, depending on the level of income or loss for such period.

Note 10 - Stockholders' Equity

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

. Stock

holders’ Equity

(a)

referred Stock

The Company is authorized to issue

5,000,000

shares of preferred stock,

$0.10

par value per share. The Company’s board of directors

may,

without further action by the stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of

5,000,000

shares of preferred stock in

one

or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which

may

be greater than the rights of the Company’s common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action.

shares of preferred stock are currently outstanding, and we have

present plan to issue any shares of preferred stock.

(b)

Common Stock

Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder action. Holders of common stock are entitled to

one

vote per share on matters to be voted on by stockholders. Holders of common stock are entitled to receive such dividends, if any, as

may

be declared from time to time by the Company’s board of directors in its discretion out of funds legally available therefore. In

event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically. As of

March

31,

2020,

dividends had been declared by the board of directors.

In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are

sinking fund provisions applicable to the common stock.

The Company had shares of common stock reserved for issuance as follows:

	March 31, 2020		December 31, 2019

Options issued and outstanding		1,650,848		1,811,652
PRSUs issued and outstanding, net of forfeitures		278,535		—
Available for future grants of equity awards		110,276		295,180
Common stock warrants		25,924,042		43,370,162
Total		27,963,701		45,476,994

(c)

Warrants

The following warrants were outstanding as of

March 31, 2020

, all of which contain standard anti-dilution protections in the event of subsequent rights offerings, stock splits, stock dividends or other extraordinary dividends, or other similar changes in the Company’s common stock or capital structure, and

none

of which have any participating rights for any losses:

Securities into which warrants are convertible	Warrants outstanding	Exercise Price		Expiration Date

Common Stock	17,005,001	$	0.30	September 2024
Common Stock	696,002	$	0.375	September 2024
Common Stock	5,685,057	$	1.10	April 2024
Common Stock	163,068	$	1.375	April 2024
Common Stock	2,000,000	$	2.50	March 2025
Common Stock	280,000	$	3.125	February 2025
Common Stock	84,000	$	3.125	March 2024
Common Stock	10,914	$	22.99	December 2026
Total	25,924,042

The

280,000

common stock warrants issued to placement agents’ designees at the closing of the

March 2020

Offering (see Note

) each entitle the holder to purchase

one

share of common stock for

$3.125

at any time within

five

years of

February 27, 2020,

the effective date of the

March 2020

Offering. The aggregate fair value of these warrants at issuance was estimated to be

$453,000,

using the Black-Scholes valuation model, using a closing stock price of

$2.34

and assumptions including estimated volatility of

98%,

a risk-free interest rate of

0.88%,

zero

dividend rate and an estimated remaining term of

4.99

years.

In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company’s control, the holders of the unexercised common stock warrants exercisable for

$0.30,

$0.375,

$1.10

and

$2.50

and those exercisable for

$3.125

expiring in

February 2025

shall be entitled to receive cash consideration equal to a Black-Scholes valuation, as defined in the warrant. If such Fundamental Transaction is

not

within the Company’s control, the warrantholders would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company’s common stock, hence these warrants are classified as a component of permanent equity.

Note 11 - Equity Incentive Plans

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

NOTE

Equity Incentive Plan

April 23, 2019,

the Company’s stockholders approved the adoption of the

2019

Plan, under which the Company is authorized to issue ISOs, NQSOs, stock appreciation rights, RSAs, RSUs, other stock awards and performance awards that

may

be settled in cash, stock, or other property. The

2019

Plan is designed to secure and retain the services of employees, directors and consultants, provide incentives for the Company’s employees, directors and consultants to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which employees, directors and consultants

may

be given an opportunity to benefit from increases in the value of the Company’s common stock. Following adoption of the

2019

Plan, all previous plans were frozen, and on forfeiture, cancellation and expiration, awards under those plans are

not

assumed by the

2019

Plan.

March 2020,

the Company granted

411,000

performance-based restricted stock unit (“PRSU”) awards to employees which vest upon the achievement of certain performance conditions, subject to each employee’s continued service relationship with the Company. As of

March

31,

2020,

all of these

411,000

PRSUs were outstanding. The related compensation cost, which is based on the grant date fair value of the Company’s common stock multiplied by the number of PRSUs granted, is recognized as an expense ratably over the estimated vesting period when achievement of the performance condition is considered probable. Based on the Company’s evaluation of the probability of achieving the performance condition as of

March

31,

2020,

stock-based compensation expense related to the PRSUs was recorded for the

three

months then ended. The Company will continue to evaluate the probability of achieving the performance conditions for the PRSUs at the end of each reporting period and, should achievement of the performance condition be assessed as probable, will record compensation expense related to the PRSUs accordingly.

stock options were awarded in the

three

months ended

March 31, 2020

2019.

A summary of stock option transactions in the

three

months ended

March 31, 2020,

is as follows:

							Weighted
	Shares			Number of			Average
	Available			Options			Exercise
	For Grant			Outstanding			Price

Balance at January 1, 2020		295,180			1,811,652		$	2.74
PRSUs granted, net of tax forfeitures		(278,535	)		—		$	—
Exercised		—			(23,606	)	$	0.77
Forfeited		85,910			(85,992	)	$	0.39
Canceled		7,721			(51,206	)	$	9.19

Balance at March 31, 2020		110,276			1,650,848		$	2.69

The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options was as follows:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Research and development	$	22	$	79
General and administrative		74		85
Total stock-based compensation	$	96	$	164

As of

March

31,

2020,

the unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was

$0.6

million, which the Company expects to recognize over an estimated weighted average period of

2.23

years.

Note 12 - Net Loss Per Share

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

. Net Loss

Per Share

The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2020			2019

Net loss	$	(1,297	)	$	(1,339	)

Shares used to compute net loss per share – basic and diluted		60,677,145			7,301,189

Net loss per share – basic and diluted	$	(0.02	)	$	(0.18	)

adjustment has been made to the net loss in the

three

months ended

March

31,

2020

2019,

as the effect would be anti-dilutive due to the net loss.

The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because they would have been antidilutive:

	Three Months Ended March 31,
	2020		2019

Options to purchase common stock		1,773,779		860,371

PRSUs		36,132		—

Warrants to purchase common stock		33,023,381		22,114

Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation		34,833,292		882,485

Table of Contents

VAXART

, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Note 13 - Restructuring Costs

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

NOTE

Restructuring Costs

Restructuring liabilities primarily consist of the estimated future obligations for contract suspension costs. These restructuring liabilities, all of which are expected to be paid in the year ending

December 31, 2020,

are recorded in other accrued liabilities in the condensed consolidated balance sheets.

The Company approved a reduction-in-force during the year ended

December 31, 2019,

for which it accrued severance and benefits charges, all of which were paid in the

three

months ended

March 31, 2020.

The Company also accrued the maximum amount potentially payable under a manufacturing work order which it suspended, recorded impairment charges against property and equipment and right-of-use assets formerly used for manufacturing covering the period in which

benefits will be derived, and incurred legal fees and accretion costs in connection with the restructuring. The Company recorded costs in the

three

months ended

March 31, 2020,

for legal fees and for accretion related to the manufacturing premises and expects to record further charges in

2020

for legal fees, broker commissions and accretion and, potentially, further impairment of a right-of-use asset if it is unable to sublease the manufacturing premises for as much as it is presently paying, or if subleasing takes longer than expected. The Company has

not

agreed to pay the full amount accrued with respect to the suspended manufacturing work order and expects to reverse part of the related charge following negotiations with the vendor.

Cumulative restructuring costs incurred and a reconciliation of the change in related liabilities during the

three

months ended

March 31, 2020,

is as follows:

	Suspension		Severance			Impairment
	of Contract		Benefits			Charges		Other			Total
	(in thousands)

Cumulative cost incurred as of March 31, 2020	$	3,223	$	368		$	1,272	$	121		$	4,984

Reconciliation of liabilities:
Balance at December 31, 2019	$	3,223	$	368		$	—	$	57		$	3,648
Period charges		—		—			—		64			64
Payments and settlements		—		(368	)		—		(112	)		(480	)
Balance at March 31, 2020	$	3,223	$	—		$	—	$	9		$	3,232

Note 14 - Subsequent Events	3 Months Ended
Note 14 - Subsequent Events	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 14 . Subsequent Events Since March 31, 2020, the Company has issued 2,064,602 shares of common stock upon the exercise of warrants for cash proceeds totaling $2.0 million.

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to these rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10 -K filed with the SEC on March 19, 2020 ( the “Annual Report”). Except as noted below, there have been no material changes to the Company’s significant accounting policies described in Note 2 to the consolidated financial statements included in the Annual Report. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.
Consolidation, Policy [Policy Text Block]	Basis of Consolidation – The condensed consolidated financial statements include the financial statements of Vaxart, Inc. and its subsidiaries. All significant transactions and balances between Vaxart, Inc. and its subsidiaries have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company places its cash and cash equivalents at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. The Company has not experienced any losses on its deposits since inception. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating. The Company generally requires no collateral from its customers.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification – Prior periods’ data is subject to reclassification to conform to the current presentation. Accordingly, $48,000 that was previously recorded as non-lease costs has been included as variable lease costs and in cash outflows related to leases in the three months ended March 31, 2019. This reclassification had no effect on reported net loss.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company has reviewed all newly-issued accounting pronouncements and concluded that they either are not applicable to the Company’s operations or no material effect is expected on its condensed consolidated financial statements as a result of future adoption.

Note 4 - Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Cash and Cash Equivalents [Table Text Block]

	March 31, 2020		December 31, 2019
	(in thousands)
Cash at banks	$	29,859	$	13,511
Money market funds		—		15
Total cash and cash equivalents	$	29,859	$	13,526

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	March 31, 2020		December 31, 2019
	(in thousands)
Royalties receivable	$	2,663	$	3,438
Customer service contracts - billed		—		181
Accounts receivable	$	2,663	$	3,619

Property, Plant and Equipment [Table Text Block]

	March 31, 2020			December 31, 2019
	(in thousands)
Laboratory equipment	$	537		$	537
Office and computer equipment		132			132
Total property and equipment		669			669
Less: accumulated depreciation		(478	)		(459	)
Property and equipment, net	$	191		$	210

Lessee, Operating Lease, Right-of-Use Assets [Table Text Block]

	March 31, 2020		December 31, 2019
	(in thousands)
Facilities	$	1,906	$	1,985
Office equipment		4		5
Right-of-use assets, net	$	1,910	$	1,990

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	March 31, 2020			December 31, 2019
	(in thousands)
Purchased technology	$	22,100		$	22,100
Intellectual property		80			80
Total cost		22,180			22,180
Less: accumulated amortization		(5,520	)		(5,087	)
Intangible assets, net	$	16,660		$	17,093

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year Ending December 31,	Amount
2020 (nine months remaining)	$	1,299
2021		1,732
2022		1,731
2023		1,732
2024		1,732
Thereafter		8,434
Total	$	16,660

Schedule of Accrued Liabilities [Table Text Block]

	March 31, 2020		December 31, 2019
	(in thousands)
Accrued compensation	$	461	$	903
Accrued clinical and manufacturing expenses		3,228		3,228
Accrued professional and consulting services		207		2
Reserve for return of royalties		178		178
Other liabilities, current portion		206		254

Total	$	4,280	$	4,565

Note 6 - Liabilities Related to Sale of Future Royalties (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

Total liability related to sale of future royalties, start of period	$	16,332
Non-cash royalty revenue paid to HCRP		(2,769	)
Non-cash interest expense recognized		491
Total liability related to sale of future royalties, end of period		14,054
Current portion		(1,513	)
Long-term portion	$	12,541

Note 7 - Leases (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year Ending December 31,
2020 (excluding the three months ended March 31, 2020)	$	781
2021		620
2022		336
2023		348
2024		360
Thereafter		121
Undiscounted total		2,566
Less: imputed interest		(440	)
Present value of future minimum payments		2,126
Current portion of operating lease liability		(855	)
Operating lease liability, net of current portion	$	1,271

Lease, Cost [Table Text Block]

	Three Months Ended March 31,
	2020			2019
Lease cost	(in thousands)
Operating lease cost	$	189		$	223
Short-term lease cost		3			3
Variable lease cost		11			48
Sublease income		(54	)		(54	)
Total lease cost	$	149		$	220

Note 10 - Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Common Stock Reserved for Issuance [Table Text Block]

	March 31, 2020		December 31, 2019

Options issued and outstanding		1,650,848		1,811,652
PRSUs issued and outstanding, net of forfeitures		278,535		—
Available for future grants of equity awards		110,276		295,180
Common stock warrants		25,924,042		43,370,162
Total		27,963,701		45,476,994

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Securities into which warrants are convertible	Warrants outstanding	Exercise Price		Expiration Date

Common Stock	17,005,001	$	0.30	September 2024
Common Stock	696,002	$	0.375	September 2024
Common Stock	5,685,057	$	1.10	April 2024
Common Stock	163,068	$	1.375	April 2024
Common Stock	2,000,000	$	2.50	March 2025
Common Stock	280,000	$	3.125	February 2025
Common Stock	84,000	$	3.125	March 2024
Common Stock	10,914	$	22.99	December 2026
Total	25,924,042

Note 11 - Equity Incentive Plans (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Share-based Payment Arrangement, Option, Activity [Table Text Block]

							Weighted
	Shares			Number of			Average
	Available			Options			Exercise
	For Grant			Outstanding			Price

Balance at January 1, 2020		295,180			1,811,652		$	2.74
PRSUs granted, net of tax forfeitures		(278,535	)		—		$	—
Exercised		—			(23,606	)	$	0.77
Forfeited		85,910			(85,992	)	$	0.39
Canceled		7,721			(51,206	)	$	9.19

Balance at March 31, 2020		110,276			1,650,848		$	2.69

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Research and development	$	22	$	79
General and administrative		74		85
Total stock-based compensation	$	96	$	164

Note 12 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,
	2020			2019

Net loss	$	(1,297	)	$	(1,339	)

Shares used to compute net loss per share – basic and diluted		60,677,145			7,301,189

Net loss per share – basic and diluted	$	(0.02	)	$	(0.18	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended March 31,
	2020		2019

Options to purchase common stock		1,773,779		860,371

PRSUs		36,132		—

Warrants to purchase common stock		33,023,381		22,114

Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation		34,833,292		882,485

Note 13 - Restructuring Costs (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

	Suspension		Severance			Impairment
	of Contract		Benefits			Charges		Other			Total
	(in thousands)

Cumulative cost incurred as of March 31, 2020	$	3,223	$	368		$	1,272	$	121		$	4,984

Reconciliation of liabilities:
Balance at December 31, 2019	$	3,223	$	368		$	—	$	57		$	3,648
Period charges		—		—			—		64			64
Payments and settlements		—		(368	)		—		(112	)		(480	)
Balance at March 31, 2020	$	3,223	$	—		$	—	$	9		$	3,232

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Mar. 02, 2020	Feb. 13, 2018
Conversion of Stock, Shares Issued (in shares)		0.22148
Proceeds from Issuance or Sale of Equity, Total	$ 10,000,000
Proceeds from Issuance or Sale of Equity, Net	9,200,000
Payments of Stock Issuance Costs	$ 775,000
The March 2020 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.50
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants and Rights Outstanding	$ 453,000
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	280,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.125
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Issued During Period (in shares)	280,000
Warrants and Rights Outstanding	$ 453,000
The March 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	4,000,000

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Variable Lease, Cost	$ 11,000	$ 48,000
Reclassification from Non-lease Cost [Member]
Variable Lease, Cost		$ 48,000

Note 3 - Fair Value of Financial Instruments (Details Textual) - Fair Value, Recurring [Member] - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Financial Liabilities Fair Value Disclosure, Total	$ 0		$ 0
Money Market Funds [Member]
Cash and Cash Equivalents, Fair Value Disclosure		$ 15,000

Note 4 - Balance Sheet Components (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Accounts Receivable, Allowance for Credit Loss, Current	$ 0		$ 0
Depreciation, Total	19,000	$ 130,000
Impairment of Property and Equipment	0	0
Amortization of Intangible Assets, Total	$ 433,000	$ 779,000
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year 109 days
Finite-Lived Intangible Asset, Useful Life (Year)	9 years 219 days
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	11 years 273 days
Finite-Lived Intangible Asset, Useful Life (Year)	7 years 273 days

Note 4 - Balance Sheet Components - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Cash at banks	$ 29,859	$ 13,511
Money market funds		15
Total cash and cash equivalents	$ 29,859	$ 13,526	$ 8,424	$ 11,506

Note 4 - Balance Sheet Components - Accounts Receivable, Net of Allowance (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts receivable	$ 2,663	$ 3,619
Royalty [Member]
Accounts receivable	2,663	3,438
Customer Service Contracts [Member]
Accounts receivable		$ 181

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 669	$ 669
Less: accumulated depreciation	(478)	(459)
Property and equipment, net	191	210
Laboratory Equipment [Member]
Property and equipment, gross	537	537
Office Equipment [Member]
Property and equipment, gross	$ 132	$ 132

Note 4 - Balance Sheet Components - Right-of-Use Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Right-of-use assets, net	$ 1,910	$ 1,990
Facilities [Member]
Right-of-use assets, net	1,906	1,985
Office Equipment [Member]
Right-of-use assets, net	$ 4	$ 5

Note 4 - Balance Sheet Components - Intangible assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Intangible assets, gross	$ 22,180	$ 22,180
Less: accumulated amortization	(5,520)	(5,087)
Intangible assets, net	16,660	17,093
Purchased Technology [Member]
Intangible assets, gross	22,100	22,100
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2020 USD ($)
2020 (nine months remaining)	$ 1,299
2021	1,732
2022	1,731
2023	1,732
2024	1,732
Thereafter	8,434
Total	$ 16,660

Note 4 - Balance Sheet Components - Accrued liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued compensation	$ 461	$ 903
Accrued clinical and manufacturing expenses	3,228	3,228
Accrued professional and consulting services	207	2
Reserve for return of royalties	178	178
Other liabilities, current portion	206	254
Total	$ 4,280	$ 4,565

Note 5 - Revenue 1 (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
Note 5 - Revenue 1 (Details Textual) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total	$ 0		$ 181,000
Contract With Customer, Asset, Revenue Recognized	120,000		21,000
Contract with Customer, Liability, Total	0		$ 0
Revenue, Remaining Performance Obligation, Amount	112,000	$ 211,000
Revenue from Contract with Customer, Including Assessed Tax	2,902,000	5,407,000
Income Tax Expense (Benefit), Total	$ 153,000	250,000
Foreign Tax Authority [Member] \| National Tax Agency, Japan [Member]
Royalty Withholding Tax	5.00%
Income Tax Expense (Benefit), Total	$ 140,000	236,000
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax	2,769,000	3,659,000
Royalty [Member] \| GSK Research and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 695,000
Royalty Percentage		7.00%
Royalty [Member] \| Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 2,769,000	$ 2,964,000
Royalty Percentage	4.00%		4.00%
Non-cash Royalty Revenue, Related to Sale of Future Royalties	$ 34,000	$ 1,748,000

Note 5 - Revenue 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01	Mar. 31, 2020	Mar. 31, 2019
Revenue, Remaining Performance Obligation, Percentage	100.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	90 days	90 days

Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) - HCRP [Member] $ in Millions	1 Months Ended
	Apr. 30, 2016 USD ($)
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest Due Each Year	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Current portion	$ (1,513)	$ (2,916)
Long-term portion	12,541	$ 13,416
HealthCare Royalty Partners III, L.P. [Member] \| Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of period	16,332
Non-cash royalty revenue paid to HCRP	(2,769)
Non-cash interest expense recognized	491
Total liability related to sale of future royalties, end of period	14,054
Current portion	(1,513)
Long-term portion	$ 12,541

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended
Note 7 - Leases (Details Textual) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Lessee, Operating Lease, Number of Right-of-Use Leases	4
Lessee, Operating Lease, Number of Right-of-Use Leases, Terminated	1
Lessee, Operating Lease, Number of Right-of-Use Leases, Subleased	1
Lessee, Operating Lease, Number Leases Exceeding One Year	3
Lessee, Operating Lease, Renewal Term (Year)	5 years
Operating Lease, Weighted Average Discount Rate, Percent	10.53%
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years 226 days
Lessee, Finance Lease, Number of Leases	0
Short-term Lease Commitment, Amount	$ 0
Operating Lease, Payments	$ 237,000	$ 247,000

Note 7 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
2020 (excluding the three months ended March 31, 2020)	$ 781
2021	620
2022	336
2023	348
2024	360
Thereafter	121
Undiscounted total	2,566
Less: imputed interest	(440)
Present value of future minimum payments	2,126
Current portion of operating lease liability	(855)	$ (841)
Operating lease liability, net of current portion	$ 1,271	$ 1,472

Note 7 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating lease cost	$ 189	$ 223
Short-term lease cost	3	3
Variable lease cost	11	48
Sublease income	(54)	(54)
Total lease cost	$ 149	$ 220

Note 8 - Secured Promissory Note Payable to Oxford Finance (Details Textual) - Loan Agreement [Member] - Oxford Finance [Member] - USD ($)		3 Months Ended
	Dec. 22, 2016	Mar. 31, 2019	Mar. 31, 2020
Long-term Debt, Gross	$ 5,000,000
Debt Instrument, Term (Year)	4 years
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	$ 325,000
Debt Instrument, Interest Rate, Effective Percentage			10.50%
Interest Expense, Debt, Total		$ 106,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 72,000
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.17%

Note 10 - Stockholders' Equity (Details Textual)	62 Months Ended
Note 10 - Stockholders' Equity (Details Textual)	Feb. 13, 2018 USD ($)	Mar. 31, 2020 $ / shares shares	Mar. 02, 2020 USD ($) yr $ / shares shares	Dec. 31, 2019 $ / shares shares
Preferred Stock, Shares Authorized (in shares) \| shares		5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.10		$ 0.10
Preferred Stock, Shares Outstanding, Ending Balance (in shares) \| shares		0		0
Dividends, Total \| $	$ 0
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares			280,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) \| shares			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.125
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants and Rights Outstanding \| $			$ 453,000
The March 2020 Offering Placement Agent Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input			2.34
The March 2020 Offering Placement Agent Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			0.98
The March 2020 Offering Placement Agent Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0.0088
The March 2020 Offering Placement Agent Warrants [Member] \| Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0
The March 2020 Offering Placement Agent Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr			4.99
First Set of Warrants Expiring September 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.30
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		0.30
Second Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		1.375
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		0.375
First Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		1.10
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		1.10
Warrants Expiring March 2025 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		2.50
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		2.50
Warrants Expiring March 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		3.125
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		$ 3.125

Note 10 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Mar. 31, 2020	Dec. 31, 2019
Common stock reserved for issuance (in shares)	27,963,701	45,476,994
Options Issued and Outstanding [Member]
Common stock reserved for issuance (in shares)	1,650,848	1,811,652
Performance-based Restricted Stock Units (PRSUs) [Member]
Common stock reserved for issuance (in shares)	278,535
Options Available for Future Grants [Member]
Common stock reserved for issuance (in shares)	110,276	295,180
Common Warrants [Member]
Common stock reserved for issuance (in shares)	25,924,042	43,370,162

Note 10 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Mar. 31, 2020 $ / shares shares
Warrants outstanding (in shares)	25,924,042
First Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	17,005,001
Exercise Price (in dollars per share) \| $ / shares	$ 0.30
Second Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	696,002
Exercise Price (in dollars per share) \| $ / shares	$ 0.375
First Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	5,685,057
Exercise Price (in dollars per share) \| $ / shares	$ 1.10
Second Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	163,068
Exercise Price (in dollars per share) \| $ / shares	$ 1.375
Warrants Expiring March 2025 [Member]
Warrants outstanding (in shares)	2,000,000
Exercise Price (in dollars per share) \| $ / shares	$ 2.50
Warrants Expiring February 2025 [Member]
Warrants outstanding (in shares)	280,000
Exercise Price (in dollars per share) \| $ / shares	$ 3.125
Warrants Expiring March 2024 [Member]
Warrants outstanding (in shares)	84,000
Exercise Price (in dollars per share) \| $ / shares	$ 3.125
Warrants Expiring December 2026 [Member]
Warrants outstanding (in shares)	10,914
Exercise Price (in dollars per share) \| $ / shares	$ 22.99

Note 11 - Equity Incentive Plans (Details Textual) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	23,606
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 0.6
Performance-based Restricted Stock Units (PRSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	411,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)	411,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 83 days

Note 11 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Shares available for grant, balance (in shares)	295,180
Number of options outstanding, beginning balance (in shares)	1,811,652
Weighted average exercise price, balance (in dollars per share) \| $ / shares	$ 2.74
Number of options outstanding, exercised (in shares)	(23,606)
Weighted average exercise price, exercised (in dollars per share) \| $ / shares	$ 0.77
Shares available for grant, forfeited (in shares)	85,910
Number of options outstanding, forfeited (in shares)	(85,992)
Weighted average exercise price, forfeited (in dollars per share) \| $ / shares	$ 0.39
Shares available for grant, canceled (in shares)	7,721
Number of options outstanding, canceled (in shares)	(51,206)
Weighted average exercise price, canceled (in dollars per share) \| $ / shares	$ 9.19
Shares available for grant, balance (in shares)	110,276
Number of options outstanding, balance (in shares)	1,650,848
Weighted average exercise price, balance (in dollars per share) \| $ / shares	$ 2.69
Performance-based Restricted Stock Units (PRSUs) [Member]
Shares available for grant, granted (in shares)	(278,535)

Note 11 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation	$ 96	$ 164
Research and Development Expense [Member]
Stock-based compensation	22	79
General and Administrative Expense [Member]
Stock-based compensation	$ 74	$ 85

Note 12 - Net Loss Per Share (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Dilutive Securities, Effect on Basic Earnings Per Share, Total	$ 0	$ 0

Note 12 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss	$ (1,297)	$ (1,339)
Shares used to compute net loss per share - basic and diluted (in shares)	60,677,145	7,301,189
Net loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.18)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Note 12 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	34,833,292	882,485
Share-based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	1,773,779	860,371
Performance-based Restricted Stock Units (PRSUs) [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	36,132
Restricted Stock Units (RSUs) [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)
Warrant [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	33,023,381	22,114

Note 13 - Restructuring Costs - Restructuring Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cumulative cost incurred	$ 4,984
Balance	3,648
Restructuring costs	64
Payments and settlements	(480)
Balance	3,232
Contract Termination [Member]
Cumulative cost incurred	3,223
Balance	3,223
Restructuring costs
Payments and settlements
Balance	3,223
Employee Severance [Member]
Cumulative cost incurred	368
Balance	368
Restructuring costs
Payments and settlements	(368)
Balance
Impairment Charges [Member]
Cumulative cost incurred	1,272
Balance
Restructuring costs
Payments and settlements
Balance
Other Restructuring [Member]
Cumulative cost incurred	121
Balance	57
Restructuring costs	64
Payments and settlements	(112)
Balance	$ 9

Note 14 - Subsequent Events (Details Textual) - Subsequent Event [Member] $ in Millions	1 Months Ended
	May 12, 2020 USD ($) shares
Stock Issued During Period, Value, Exercise of Common Stock Warrants (in shares) \| shares	2,064,602
Proceeds from Warrant Exercises \| $	$ 2